Possible Cardiac Side Effects from Monkeypox Vaccination

Monkeypox vaccines include ACAM2000 (used for Smallpox, recently FDA approved for Monkeypox), JYNNEOS, and modified vaccinia Ankara

The at-risk population is young men who are at the highest risk of idiopathic and COVID-19 vaccine myocarditis at baseline.

ACAM2000 has been reported to have major cardiovascular adverse events such as myocarditis, dilated cardiomyopathy, and heart failure.

Whereas JYNNEOS and modified vaccinia Ankara are associated with minor cardiovascular adverse events such as tachycardia, palpitation, electrocardiogram changes such as T wave inversion, and ST elevation in the peer-reviewed literature.

The CDC has reported serious myocarditis from the Bavarian Nordic JYNNEOS vaccine requiring hospitalization of young men.

Shrestha AB, Mehta A, Zahid MJ, Candelario K, Shrestha S, Pokharel P. Concerns over cardiovascular manifestations associated with monkeypox immunization: a literature review. Ann Med Surg (Lond). 2023 May 19;85(6):2797-2801. doi: 10.1097/MS9.0000000000000861. PMID: 37363545; PMCID: PMC10289523.

A review by Shreshtha et al indicates heart damage from Monkeypox vaccination may come from an off-target attack on the heart by antibodies raised by the vaccines.

The paper concludes more research is needed for safer vaccines.

Because Monkeypox is largely a self-limited skin rash in immunocompetent individuals and easily treated with oral or intravenous tecovirimat, vaccination is a high-risk public health intervention.

If widely applied in the Congo we can expect to see rising numbers heart failure and sudden death in vaccine recipients.

See more here substack.com

Header image: BBC

About the author: Peter McCullough is a practicing internist, cardiologist, and epidemiologist in Dallas, Texas. He studies the cardiovascular complications of both the viral infection and the injuries developed from COVID vaccines. He has dozens of peer-reviewed publications on COVID, multiple U.S. and state Senate testimonies, and has commented extensively on the medical response to the COVID crisis on major media outlets.

Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.

Leave a comment

Save my name, email, and website in this browser for the next time I comment.
Share via